Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPX-351 (cytarabine + daunorubicin)
- Development stage
- Phase 4
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CPX-351 (Vyxeos) is a liposomal encapsulation of cytarabine and daunorubicin in a fixed 5:1 molar ratio. This formulation is designed to optimize the synergistic delivery of the two drugs to leukemia cells while reducing systemic exposure and toxicity. Cytarabine is a pyrimidine nucleoside analog that, once phosphorylated, inhibits DNA polymerase and DNA synthesis. Daunorubicin is an anthracycline that intercalates into DNA and inhibits topoisomerase II, leading to DNA strand breaks and apoptosis. CPX-351 was developed by Celator Pharmaceuticals (acquired by Jazz Pharmaceuticals) and is FDA-approved for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
- Brand names
- Vyxeos
- Other names
- daunorubicin and cytarabine liposomeliposomal cytarabine and daunorubicin
02
Targets
DNADNA polymerase familyDCK (Deoxycytidine kinase)TOP2B (DNA topoisomerase II beta)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on CPX-351 (cytarabine + daunorubicin).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPX-351 (cytarabine + daunorubicin).